ClinicalTrials.gg
CompletedNCT06703658Updated Mar 21, 2025

A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus

A Phase 1 interventional study of AZD5004(Part A) and Placebo(Part A) in Healthy Participants and Type 2 Diabetes, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Enrollment
14th of 18
35 · median 57
Started
2024
with 4 others
Phase 1
11 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 5 that started in 2024, is one of 11 in phase 1, and was the 6th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This Phase I study will gather important information on the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5004 in both healthy Japanese participants and Japanese participants with T2DM.

Read the detailed description

This is a placebo-controlled study to assess the safety, efficacy, tolerability, and PK of single and repeated dosing of AZD5004 compared with placebo.

Participants who are eligible according to the inclusion/exclusion criteria will be randomized to receive AZD5004 or matching placebo.

The study will comprise:

  1. A Screening Period of maximum 28 days.
  2. A Treatment Period of 1 day(Part A) or 105 days (Part B).
  3. A final Follow-up Visit approximately 7 days(Part A) or 14 days(Part B) after the last study intervention administration.
03

Conditions studied

  • Healthy Participants
  • Type 2 Diabetes

Keywords

  • Obesity
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Japanese men or women, and 18-65 years of age inclusive, at the time of signing the .

Inclusion Criteria for Part A:

  • ≤ 6.0%.
  • Body weight ≥ 50.0 kg and within the range 18.0-32.0 kg/m2.

Inclusion Criteria for Part B:

  • HbA1c ≥ 6.5% and ≤ 10.5%.
  • Not on any other diabetic medications.
  • Body weight ≥ 60.0 kg and BMI within the range 24.0-35.0 kg/m2

Exclusion Criteria:

  • Has a acute or chronic medical condition or disease.
  • History of acute pancreatitis and chronic pancreatitis, gallstones.
  • Abnormal renal function.
  • Known clinically significant gastric emptying abnormality
  • Significant hepatic disease.
  • Uncontrolled thyroid disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Part A-AZD5004

    Participants will receive AZD5004 orally.

    Drug: AZD5004(Part A)

  • Placebo comparator
    Part A-Placebo

    Participants will receive matching Placebo orally.

    Drug: Placebo(Part A)

  • Experimental
    Part B-AZD5004

    Participants will receive AZD5004 orally.

    Drug: AZD5004(Part B)

  • Placebo comparator
    Part B-Placebo

    Participants will receive matching Placebo orally.

    Drug: Placebo(Part B)

Interventions

  • Single dose of AZD5004 oral on Day1

  • DrugPlacebo(Part A)

    Single dose of placebo oral on Day1

  • AZD5004 will be administered as an oral tablet once daily.

  • DrugPlacebo(Part B)

    Placebo will be administered as an oral tablet once daily.

06

What researchers measure

Primary outcomes

  1. PartA: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of AZD5004 following single oral doses in healthy participants.

    Time frame: From screening (Day -28) to last follow up visit (Day 8)

  2. PartB: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of AZD5004 following multiple oral ascending doses in participants with T2DM.

    Time frame: From screening (Day -28) to last follow up visit (Day 119 )

Secondary outcomes

  1. PartB: AUC0-4 for glucose, insulin and C-peptide for MMTT

    To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: From Day 1 to Day 105

  2. PartB: Absolute change from baseline to Day 105 in fasting plasma glucose

    To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: From Day 1 to Day 105

  3. PartB: % change from baseline to Day 105 in HOMA-IR

    To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: From Day 1 to Day 105

  4. PartB: The proportion of time in hyperglycaemia /hypoglycaemia over the last 7-day intervals at each dose level in CGM

    To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: From Day 1 to Day 106

  5. PartB: % change from baseline to Day 105 in body weight (kg)

    To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: From Day 1 to Day 105

  6. PartB: % change from baseline to Day 105 in waist circumference (cm)

    To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: From Day 1 to Day 105

  7. PartA: Area under the Plasma Concentration vs. Time Curve(AUC0-24)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  8. PartA: Area under the Plasma Concentration vs. Time Curve from Zero until the Time of the Last Concentration above the Limit of Quantification(AUC0-tlast)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  9. PartA: Area under the Plasma Concentration vs. Time Curve from Zero to Infinity(AUC0-inf)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  10. PartA: Maximum Observed Plasma Concentration(Cmax)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  11. PartA: Plasma Concentration at 24 Hours Post-Dose(C24h)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  12. PartA: Time of Occurrence of Maximum Plasma Concentration(tmax)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  13. PartA: Lag Time before Observation of Quantifiable Analyte Concentrations in Plasma(tlag)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  14. PartA: Half-Life(t1/2)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  15. PartA: Last measurable Non-Zero Concentration(Clast)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  16. PartA: Last measurable Non-Zero ConcentrationTime to Last Detectable Concentration(tlast)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  17. PartA: Apparent Oral Clearance(CL/F)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  18. PartA: Cumulative Urinary Excretion(Ae)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  19. PartA: Clearance(CLR)

    To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD

    Time frame: From Day 1 to Day 6

  20. PartB: Area under the Plasma Concentration vs. Time Curve(AUC0-24)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 1

  21. PartB: Maximum Observed Plasma Concentration(Cmax)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 1, Day 49, Day 63, Day 77, Day91, Day105

  22. PartB: Plasma Concentration at 24 Hours Post-Dose(C24h)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 1

  23. PartB: Time of Occurrence of Maximum Plasma Concentration(tmax)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 1, Day 49, Day 63, Day 77, Day91, Day105

  24. PartB: Lag Time before Observation of Quantifiable Analyte Concentrations in Plasma(tlag)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 1

  25. PartB: Area under the Plasma Concentration vs. Time Curve over the Dosing Interval(AUC0-τ)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 49, Day 63, Day 77, Day 91, Day 105

  26. PartB: Observed Concentration at the End of the Dosing Interval(Cτ)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 49, Day 63, Day 77, Day 91, Day 105

  27. PartB: Half-Life(t1/2)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 49, Day 63, Day 77, Day 91, Day 105

  28. PartB: Apparent Oral Clearance(CL/F)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 49, Day 63, Day 77, Day 91, Day 105

  29. PartB: Cumulative Urinary Excretion(Ae)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 105

  30. PartB: Clearance(CLR)

    To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD

    Time frame: Day 105

07

Study locations

1 site
  • Research Site
    Osaka-shi, 532-0003, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Mar 2025, 4 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 4 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Nov 25, 2024
StartActual
Nov 2, 2024
Primary completionActual
Mar 13, 2025
CompletionActual
Mar 13, 2025
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06703658
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Nov 2, 2024
Primary completion
Mar 13, 2025
Completion
Mar 13, 2025
Last update
Mar 21, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion